CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

ST-920Positive
AI Analysis

Summary

PTC Therapeutics completed its acquisition of ST-920, a BLA-stage Fabry Disease gene therapy from Sangamo Therapeutics, with BLA submission expected in Q4 2026.

Outcome Details

Acquisition completed

Importance:7/10
Sentiment:
0.70
acquisitiongene therapyBLA submissionFabry Disease
Related Companies

Read the original article

Published by PR Newswire Biotech on September 21, 2026 8:30 PM

Read Original